Optellum

"Early data from the implementation of this technology at UConn Health shows an uptick in lung cancer diagnoses, particularly at earlier stages. Over the past six months, we have identified an increasing number of patients with stage one lung cancer—cases that are now being successfully treated and cured often through resection."   We are thrilled to share a recent article from UConn Today highlighting the significant strides UConn Health has made in early lung cancer detection.    By integrating Optellum's Virtual Nodule Clinic (VNC) software, UConn Health patients have benefited from earlier diagnoses and improved outcomes thanks to the ability to identify and manage lung nodules better.   The VNC software uses artificial intelligence to analyze chest CT scans and radiology reports, identifying and helping to manage incidental lung nodules that might otherwise be overlooked. This proactive approach helps more patients receive timely evaluations, facilitating early intervention when necessary.   Quentin Chometon, Optellum's Vice President of Research and Development, expressed his enthusiasm: "It's fantastic to hear first-hand from our partners about the impact our technology is having on their patients. Dr. Ibrahim and his team at UConn are leading the way in the early diagnosis of lung cancer."   For more information on UConn Health's advancements in lung cancer detection, please read the full article here: https://lnkd.in/e4Dh7Gkz   #lungcancerawareness #lungcancer #customersuccess  

🎯 100% Sensitivity & 87% Accuracy 🎯   At the recent Southern Thoracic Surgical Association meeting in Austin, TX, Dr. John Kuckelman from the Division of Thoracic Surgery at the Medical College of Georgia at Augusta University, shared remarkable findings on the impact of Optellum’s AI technology for lung cancer prediction—known as the Lung Cancer Prediction (LCP) score.   The study revealed that the LCP score achieved 100% sensitivity in predicting lung cancer, with an overall accuracy of 87%. Notably, among patients identified by LCP as having lung cancer and referred for biopsy, two-thirds were initially diagnosed as non-cancerous but later underwent surgical resection that confirmed malignancy. This suggests that, at least in the cases studied, LCP outperforms biopsy in predicting early-stage lung cancer!   🌎 What Does This Mean for Patients?   Potentially, more early-stage lung cancer cases can be diagnosed sooner, enabling earlier and more effective treatment while optimizing the use of interventional procedures.   Additionally, LCP is reimbursable at $650 under Medicare and commercial insurance plans. Want to see how Optellum’s LCP can work for you? Request a demo today 👉https://lnkd.in/dgy9Hxzj   Missed the event? View our case study, including insights from Daniel L Miller MD from the Georgia Cancer Center at Augusta University below 👇 #LungCancer #AIinMedicine #Pulmonology

🫁 November is Lung Cancer Awareness Month 🫁 Our mission is to help healthcare providers diagnose and treat lung disease at the earliest possible stage so patients have the best chance at positive outcomes. As it's Lung Cancer Awareness Month, we wanted to highlight why we focus on lung health. Lung cancer remains one of the most impactful cancers worldwide, but early detection and treatment can significantly mitigate its effects. What is the impact of lung cancer? 👇 Incidence and mortality 👉 Lung cancer is the third most common cancer in the UK and the US(1,2). 👉 Lung cancer leads all cancers in mortality rates, accounting for 21% of cancer deaths in the UK and 22% in the US(4). Screening programs 👉 Screening programs are available in both the UK and the US; however the reported uptake rates vary significantly, from as low as 8.6% in some US states(5) to approximately 42% in the UK(6). 💡 This highlights the need for increased public awareness and other strategies for identifying lung nodules. Survival rates 👉 Approximately 9% of people diagnosed with lung cancer in England survive their disease for ten years or more(7). 👉 In the US, between 2013-2019, 48% of lung cancers were only diagnosed once they had metastasized. At this stage, the 5-year survival rate was only 8%. However, when the tumor was identified early at the localized phase, the 5-year survival rate was 63%(8). 💡 This is due to treatment options being more curative in the early stages. What are the risk factors? Smoking and secondhand smoke remain the primary risk factors for lung cancer. Other risk factors include exposure to radon, hazardous chemicals, and environmental pollutants. We support healthcare providers in the early identification and treatment of lung cancer through our Virtual Nodule Clinic, helping to solve lung cancer. Learn more about our work: optellum.com #LungCancerAwarenessMonth #EarlyDetection #LungHealth Sources: https://lnkd.in/dyXZRnjQ https://lnkd.in/dASwwfiX https://lnkd.in/dep44kNi https://lnkd.in/dAe9v2Sq https://lnkd.in/dB6Bbczz https://lnkd.in/dX5G2F_u https://lnkd.in/dpHQSm_Q https://lnkd.in/dU94kFVj

📣 Optellum's Virtual Nodule Clinic is now available on the G-Cloud 14 Framework 📣 We are thrilled to announce our inclusion on the UK government's coveted G-Cloud 14 framework, which is designed to provide quick and easy access to thoroughly vetted technology and innovations for public sector organizations. To become accredited on the G-cloud 14 framework, we had to demonstrate: ✅ Robust clinical evidence ✅ Regulatory clearances such as the UKCA and CE mark ✅ Compliance with stringent cybersecurity and information security standards ✅ ISO quality adherence   What does this mean for NHS organizations? NHS organizations can now procure our lung cancer software solution, Optellum Virtual Nodule Clinic (VNC) in a more streamlined and efficient manner, ensuring that every lung cancer patient receives the earliest possible diagnosis and treatment, maximizing their chances of survival. 👉 Read more about VNC, and how NHS organizations can benefit: https://lnkd.in/e6sy8baQ #LungHealth #Optellum #LungCancer

We're proud to share this update from one of our incredible customers: The Queen's Health Systems!    Thank you to everyone involved for their dedication and shared vision of a future where early, precise diagnosis and targeted lung cancer treatments are accessible to all patients no matter where they live.   #LungCancerAwareness #AIInMedicine #LungCancer

📣 Optellum Awarded Grant to Advance AI Imaging Technology 📣 💡 Optellum, a leading innovator in artificial intelligence (AI) and medical imaging for lung cancer, has secured joint funding from the NIHR (National Institute for Health and Care Research) and the Office for Life Sciences’ (OLS) new £148 million cancer programme to conduct a study on the impact of its AI product on early diagnosis of lung cancer. 🤝 In partnership with Leeds Teaching Hospitals NHS Trust, the study aims to evaluate the effectiveness of the AI product in relieving pressure on radiology departments and improving patient outcomes by enhancing diagnostic accuracy and supporting the early detection of cancers. 👉 Read the full release: https://lnkd.in/eWHeCSkt #LungHealth #Optellum #LungCancer

Join us at American College of Chest Physicians CHEST 2024 in Boston! Visit us at Booth #790 today until October 9 to learn how your thoracic care teams can: 🔍 Find more suspicious lung nodules 📈 Streamline and increase patient enrolments ⏰ Deliver life-saving procedures sooner See you in Boston! 👋 #CHEST2024 #ThoracicCare #ThoracicSurgery #Pulmonology #AIinHealthcare #LungHealth #Optellum #LungCancer #RoboticBronchoscopy #RoboticBiopsy

At the American Association for Thoracic Surgery (AATS) International Thoracic Surgical Oncology Summit 2024 last week, Dr Adam Lee of Jupiter Medical Center presented early results showing Optellum Virtual Nodule Clinic helped: 🎯 Increase early-stage lung cancer diagnosis rates from 46% to 85% ⏲ Increase workflow efficiency by 30%, indicating faster time to diagnosis With these excellent results, Dr. Lee and the Jupiter Medical Center team are leading the way in helping solve lung cancer. For more details, check out the abstract of the presentation here 👉 https://lnkd.in/ePzCmAuX #lungcancer #healthcareinnovation #earlydiagnosis #AATS #floridahealthcare #lungnodules #pulmonology #thoraciconcology

We're pleased to feature in the Tampa Bay Business Journal, discussing our visit to #Tampa as part of the UK trade delegation to #Florida, along with Niall Mackenzie CBE, His Majesty's Trade Commissioner for North America and Rufus Drabble, His Majesty's Consul General in Miami. Our CEO shared insights on how our #AI / #DeepLearning technology in our flagship product, Virtual Nodule Clinic, helps identify lung cancer early. We look forward to potential partnerships with key healthcare providers & innovators in the #TampaBay region. And we’re eager to connect with other stakeholders in the #Floridahealthcare community to build a brighter future for lung cancer care, so please reach out! ☀ Read the full article here 👉 https://lnkd.in/eur4aF9P #HealthcareInnovation #LungCancerAwareness #AIinHealthcare #Optellum #TampaBayHealth #UKFloridaTradeCorridor #EarlyDetection #LifeSciences Thanks to the panellists at the Tampa event, Jennifer Crabtree, Craig Anderson, Lauren Key, and Matthew Tierney and hosts Tampa Bay Economic Development Council. Additional thanks to Anjelica Rubin, Diana Peralta, Autumn Waska, MBA, MCTM, Gaby Bonetti, Anne van Besouw, Department for Business and Trade, British Consulate-General Miami, Tampa General Hospital, BayCare Health System. Johnathan Watkins

We're thrilled to showcase how our AI-powered solutions, combined with advanced robotics and imaging, are transforming precision lung interventions and improving patient outcomes. Discover the future of lung cancer care at #AABIP2024 booths #7A (Optellum) and #26 (GE HealthCare) from August 22-24 in Charlotte, NC. Learn how our FDA-approved Virtual Nodule Clinic is revolutionizing early lung cancer diagnosis and treatment, enabling more accurate biopsies saving patients' lives. Read more here https://lnkd.in/egCg2Twu #LungCancer #AIHealth #MedTech #PrecisionMedicine #AABIP